Breathe easy. HiccAway relieves hiccups instantly. HiccAway/Instagram

Humans are weird. Take, as a perfect example, the phenomenon of hiccups — the sudden and involuntary spasm of the diaphragm muscle between regular breaths. All humans experience them, and so do other mammals and even amphibians. But we’re guessing other animals don’t approach treating hiccups in the wacky ways humans do.

For instance, some less-than-successful hiccup remedies of lore include sipping water upside down (and subsequently trying to not drown), holding one’s breath for a long time (and often hiccupping throughout the hold anyway), sucking on a peppermint, gagging oneself or pulling on the tongue, and even gobbling up a spoonful of peanut butter to help change the breathing and swallowing pattern.

The truth is those ideas are mostly a waste of breath. Luckily, one San Antonio doctor has invented a device that supposedly instantly relieves hiccups — and his invention is getting so much attention that he’s even hooked a chance to pitch the product on a new episode of ABC’s entrepreneurial-focused reality show, Shark Tank.

Dr. Ali Seifi, a neurointensivist at UT Health San Antonio and the inventor of the aptly named HiccAway, will appear on an episode of Shark Tank that airs tonight, January 21 at 7 pm.

HiccAway, a straw-like device that a hiccup sufferer uses to sip water through, is likely to wow the sharks — maybe even take their breath away? — as it is the world’s first scientifically proven medical product that safely relieves hiccups.

In fact, HiccAway was recently the subject of an article in JAMA Network Open, a publication of the Journal of the American Medical Association Network. The article addresses a four-month cross-sectional study of 249 participants from multiple countries that found that HiccAway stopped hiccups in almost 92 percent of cases and was rated a heck of a lot more favorably than home remedies.

“I believe that the science behind our product is what makes our product trustworthy and reliable. There are many hiccup remedies that are all hit and miss with no exact science to them,” Seifi says. “Some healthcare products claim they can cure a medical condition, but they don’t have scientific backup to support the product. I can confidently state that HiccAway is one of the few products on Shark Tank so far with a strong published research study as a backup.”

While hiccups are simply an annoyance for most of us, they can also be chronic for patients with cancer, meningitis, multiple sclerosis, stroke, traumatic brain or thoracic injury, and even for patients who have had surgery that requires anesthesia.

“After I witnessed my own neurology patients suffering from hiccups without an effective treatment, I was inspired to develop a safe and effective device that would be simple to use and easily available to all people,” Seifi says. “When you forcefully sip water through the device, it keeps the phrenic and vagus nerves occupied, so they don’t have enough time to cause unwanted spasms in the diaphragm. This interruption stops the hiccups.”

While the HiccAway device is already available to purchase through hiccaway.com and on Amazon, as well as at walmart.com and even in H-E-B stores throughout South Texas and at heb.com, Shark Tank (which boasts a viewing audience of about 7 million) could propel HiccAway and Seifi into a new realm of entrepreneurial success.

“For me, the experience was surreal,” says Victor Fehlberg, president and CEO of Higher Innovations Inc., which manufactures and distributes HiccAway from the Denver area. “It took so long to prepare, so much time was spent waiting, that when the pitch and appearance were finally recorded, it went too fast. It was like I was dreaming because it had been so long in the making.”

The Shark Tank appearance is likely a dream come true for Seifi and the HiccAway team — and a total breath of fresh air for the hiccup-suffering public.

------

This article originally ran on CultureMap.

There's a growing need for physician-scientists who can see from both sides of the table. Miguel Tovar/University of Houston

University of Houston researchers on why bridging the gap between academia and clinicians is key

Beaker to bedside

Physician-scientists are a group of specialized researchers at the intersection of medicine and technology. Earning both medical degrees and Ph.D.s, they offer a perspective beyond the scope of clinical practice.

Three such researchers discussed how they make the connections between discovery and patient care.

Why a dual education matters

Shaun Xiaoliu Zhang, director of the Center for Nuclear Receptors and Cell Signaling at the University of Houston and M.D. Anderson professor of biology and biochemistry, knows exactly what the clinical demands are.

"I can see from the M.D. perspective, but at the same time I have a Ph.D. — I know how to design research properly," he says. "In the clinic, you're faced with reality that a patient is struggling but you don't have the tools to treat those patients. If you engage in research you can create a tool."

Zhang says clinicians know the need but may struggle to design a solution. A Ph.D., on the other hand, may only know basic research.

Renowned hormone researcher Jan-Åke Gustafsson, Robert A. Welch professor of biology and biochemistry and founding director of the Center for Nuclear Receptors and Cell Signaling, agrees.

"The dual education makes it possible for you to see which diseases are in need of more research, drugs and so on," he says.

Physician-scientists are the driving force behind many advances of modern medicine.

"The way I look at it is, practicing medicine is relatively easy but coming up with the next diagnostic device or the next treatment for a disease is way more difficult, way more challenging," says Chandra Mohan, Hugh Roy and Lillie Cranz Cullen Endowed professor of biomedical engineering at UH.

"You see patients with certain diseases, and you know there's a dire need for better diagnostics, earlier treatment, earlier diagnosis with fewer side effects," he says.

While researchers spend time primarily in the laboratory and clinical practitioners interact with patients, they both want to make an impact.

"We have made some discoveries which have led to the development of new drugs and better understanding of certain diseases," says Gustafsson. "There's a great satisfaction that it may help people to get healthy."

Traditional research brings value to a university

The synergy of this dual education makes these investigators valuable not only to academia, but also to medical science.

"I can't imagine doing translational research without medical training," Zhang says. "If you have this part without the other, you don't know where to go. With medical training, you know exactly which direction to go."

Mohan echos that assessment.

"When you start doing research there are so many questions you can answer," he says. "Sometimes there are questions which are just too basic. They're too far removed from how it will impact a patient's life. So what are the most important questions? I think questions that really make a difference in the patient's life are the most important."

Zhang notes that the National Institutes of Health has switched its funding philosophy — once focused on basic science, it now is more interested in translational research, with a direct relationship to patient health.

As physician-scientists, these "translators" of medical research are able to bridge the chasm.

Amr Elnashai, vice president/vice chancellor of research and technology transfer at UH, says physician-scientists play an important role.

"The increasing importance of deploying technology in medicine renders it essential for a progressive research university to hire medical Ph.D. holders who are in an ideal position to bridge the gap between engineering and science on the one hand, and the broad field of medicine on the other," he says.

Research groups that bring both fields together not only have a much higher probability of impacting lives by adopting the latest technology in medical applications, he adds, but they also give interdisciplinary teams greater access to specific funding pursue such solutions.

In that sense, says Elnashai, medical Ph.D. researchers play an important part of the future research university.

------

This article originally appeared on the University of Houston's The Big Idea.

Nitiya Spearman is the internal communications coordinator for the UH Division of Research.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”

Houston business mogul Tilman Fertitta acquires Caesars in $17.6B deal

Money Moves

Houston billionaire Tilman Fertitta may currently be serving as America’s ambassador to Italy, but his company is as busy as ever. Fresh off its move to revive the Houston Comets WNBA franchise, his company, Fertitta Entertainment, has announced a $17.6 billion deal to acquire Caesars Entertainment, Inc.

Speculation about the deal has been circulating since at least March, according to various media reports. The deal combines Fertitta’s well-known Golden Nugget casino brand with all of the properties in the Caesars’ portfolio, including Las Vegas hotels Caesars Palace, Harrah's, Paris Las Vegas, Planet Hollywood, Horseshoe, The LINQ Hotel, Flamingo, and The Cromwell.

Overall, the combined company will include 60 domestic casino resorts and gaming facilities; online gaming including sports betting, iCasino, and Caesar’s online poker platform; retail sports betting at over 200 third-party locations through the William Hill brand; and over 550 Fertitta Entertainment outlets, including more than 450 Landry's full-service restaurants across America. The companies will combine their loyalty programs, Caesars Rewards, Golden Nugget's 24 Karat Select Club, and Landry's Select Club.

The terms will see Caesars’ shareholders receive $31 per share. Fertitta Entertainment will also acquire approximately $11.9 billion of Caesars' outstanding debt.

The transaction will be financed through a combination of equity contributed by Fertitta Entertainment, assumed Caesars' debt, and new committed debt financing arranged by a group consisting of 10 banks. It is subject to approval by Caesars’ shareholders and government regulators.

Fertitta Entertainment is the Houston-based company behind a diverse array of hospitality businesses, including The Golden Nugget, The Post Oak Hotel, River Oaks District, the Kemah Boardwalk, and Houston’s Downtown Aquarium.

It also operates a number of prominent restaurant brands, including Mastro's Restaurants, Del Frisco's Double Eagle Steakhouse, Morton's The Steakhouse, The Palm, McCormick & Schmick's, Landry's Seafood House, The Oceanaire Seafood Room, and Saltgrass Steak House.

---

This article first appeared on CultureMap.com.